Kinome-wide siRNA screening identifies molecular targets mediating the sensitivity of pancreatic cancer cells to Aurora kinase inhibitors

Biochemical Pharmacology

Volumn 83, Issue 4, 2012, Pages 452-461

  Xie, Lifang ^a   Kassner, Michelle ^a   Munoz, Ruben M ^a   Que, Qiang Q ^a   Kiefer, Jeff ^a   Zhao, Yu ^a   Mousses, Spyro ^a   Yin, Hongwei H ^a   Von Hoff, Daniel D ^a   Han, Haiyong ^a  

^a Translational Genomic Research Institute (TGen)   (United States)

Author keywords

Aurora kinase; Imatinib; Pancreatic cancer; PDGFR; siRNA screening

Indexed keywords

DANUSERTIB; IMATINIB; N [4 [6 METHOXY 7 (3 MORPHOLINOPROPOXY) 4 QUINAZOLINYLAMINO]PHENYL]BENZAMIDE; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; POLYPEPTIDE; SMALL INTERFERING RNA; SORAFENIB; TOZASERTIB;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CONTROLLED STUDY; GENE IDENTIFICATION; GENE OVEREXPRESSION; GENE SILENCING; GENE TARGETING; GENETIC SCREENING; HUMAN; HUMAN CELL; PANCREAS CANCER; PRIORITY JOURNAL; SENSITIZATION;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DRUG SCREENING ASSAYS, ANTITUMOR; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; PANCREATIC NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; RNA INTERFERENCE; RNA, SMALL INTERFERING;

EID: 84855782760     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2011.11.005     Document Type: Article

References (61)

1. A. Vincent, J. Herman, R. Schulick, R.H. Hruban, and M. Goggins Pancreatic cancer Lancet 378 2011 607 620
2. M.J. Moore, D. Goldstein, J. Hamm, A. Figer, J.R. Hecht, and S. Gallinger Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a Phase III trial of the National Cancer Institute of Canada Clinical Trials Group J Clin Oncol 25 2007 1960 1966 (Pubitemid 46972777)
3. Von Hoff DD, Ramanathan R, Borad M, Laheru D, Smith L, Wood T, et al. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a Phase I/II trial. J Clin Oncol 2011; Published online on October 3, 2011.
4. T. Conroy, F. Desseigne, M. Ychou, O. Bouche, R. Guimbaud, and Y. Becouarn FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer N Engl J Med 364 2011 1817 1825
5. S.L. Warner, D.J. Bearss, H. Han, and D.D. Von Hoff Targeting Aurora-2 kinase in cancer Mol Cancer Ther 2 2003 589 595
6. M. Carmena, and W.C. Earnshaw The cellular geography of Aurora kinases Nat Rev Mol Cell Biol 4 2003 842 854 (Pubitemid 37411723)
7. S. Sen, H. Zhou, and R. White A putative serine/threonine kinase encoding gene BTAK on chromosome 20q13 is amplified and overexpressed in human breast cancer cell lines Oncogene 14 1997 2195 2200 (Pubitemid 27248231)
8. J. Bischoff, L. Anderson, Y. Zhu, K. Mossie, L. Ng, and B. Souza A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers EMBO J 17 1998 3052 3065 (Pubitemid 28254378)
9. W. Lok, R.Q. Klein, and M.W. Saif Aurora kinase inhibitors as anti-cancer therapy Anti-Cancer Drugs 21 2010 339 350
10. C. Pirker, D. Lotsch, S. Spiegl-Kreinecker, F. Jantscher, H. Sutterluty, and M. Micksche Response of experimental malignant melanoma models to the pan-Aurora kinase inhibitor VE-465 Exp Dermatol 19 2010 1040 1047
11. A. Kanda, H. Kawai, S. Suto, S. Kitajima, S. Sato, and T. Takata Aurora-B//AIM-1 kinase activity is involved in Ras-mediated cell transformation Oncogene 24 2005 7266 7272 (Pubitemid 41622230)
12. P. Meraldi, R. Honda, and A.E. Nigg Aurora-A overexpression reveals tetraploidization as a major route to centrosome amplification in p53-/- cells EMBO J 21 2002 483 492 (Pubitemid 34174030)
13. S. Rojanala, H. Han, R.M. Munoz, W. Browne, R. Nagle, and D.D. Von Hoff The mitotic serine threonine kinase, Aurora-2, is a potential target for drug development in human pancreatic cancer Mol Cancer Ther 3 2004 451 457 (Pubitemid 39193722)
14. H. Han, D.J. Bearss, L.W. Browne, R. Calaluce, R.B. Nagle, and D.D. Von Hoff Identification of differentially expressed genes in pancreatic cancer cells using cDNA microarray Cancer Res 62 2002 2890 2896 (Pubitemid 34525776)
15. D. Li, J. Zhu, P.F. Firozi, J.L. Abbruzzese, D.B. Evans, and K. Cleary Overexpression of oncogenic STK15/BTAK/Aurora A kinase in human pancreatic cancer Clin Cancer Res 9 2003 991 997 (Pubitemid 36323702)
16. S.L. Warner, S. Bashyam, H. Vankayalapati, D.J. Bearss, H. Han, and D.D. Von Hoff Identification of a lead small-molecule inhibitor of the Aurora kinases using a structure-assisted, fragment-based approach Mol Cancer Ther 5 2006 1764 1773 (Pubitemid 44323244)
17. E.A Harrington, D. Bebbington, J. Moore, R.K. Rasmussen, A.O. Ajose-Adeogun, and T. Nakayama VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo Nat Med 10 2004 262 267 (Pubitemid 38667616)
18. E.H. Rubin, G.I. Shapiro, M.N. Stein, P. Watson, D. Bergstrom, and A. Xiao A Phase I clinical and pharmacokinetic (PK) trial of the aurora kinase (AK) inhibitor MK-0457 in cancer patients J Clin Oncol 24 18S 2006 Abstract 3009
19. D. Bebbington, H. Binch, J.D. Charrier, S. Everitt, D. Fraysse, and J. Golec The discovery of the potent aurora inhibitor MK-0457 (VX-680) Bioorg Med Chem Lett 19 2009 3586 3592
20. D. Pluim, J.H. Beijnen, J.H. Schellens, and O. van Tellingen Simultaneous determination of AZD1152 (prodrug) and AZD1152-hydroxyquinazoline pyrazol anilide by reversed phase liquid chromatography J Chromatogr B Analyt Technol Biomed Life Sci 877 2009 3549 3555
21. R.W. Wilkinson, R. Odedra, S.P. Heaton, S.R. Wedge, N.J. Keen, and C. Crafter AZD1152, a selective inhibitor of Aurora B kinase, inhibits human tumor xenograft growth by inducing apoptosis Clin Cancer Res 13 2007 3682 3688 (Pubitemid 46955132)
22. G. Gorgun, E. Calabrese, T. Hideshima, J. Ecsedy, G. Perrone, and M. Mani A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma Blood 115 2010 5202 5213
23. J.M. Maris, C.L. Morton, R. Gorlick, E.A. Kolb, R. Lock, and H. Carol Initial testing of the aurora kinase A inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP) Pediatr Blood Cancer 55 2010 26 34
24. P. Carpinelli, R. Ceruti, M.L. Giorgini, P. Cappella, L. Gianellini, and V. Croci PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer Mol Cancer Ther 6 2007 3158 3168
25. R.B. Cohen, S.F. Jones, C. Aggarwal, M. von Mehren, J. Cheng, and D.R. Spigel A phase I dose-escalation study of danusertib (PHA-739358) administered as a 24-hour infusion with and without granulocyte colony-stimulating factor in a 14-day cycle in patients with advanced solid tumors Clin Cancer Res 15 2009 6694 6701
26. N. Steeghs, F.A.L.M. Eskens, H. Gelderblom, J. Verweij, J.W.R. Nortier, and J. Ouwerkerk Phase I pharmacokinetic and pharmacodynamic study of the aurora kinase inhibitor danusertib in patients with advanced or metastatic solid tumors J Clin Oncol 27 2009 5094 5101
27. D. Benten, G. Keller, A. Quaas, J. Schrader, A. Gontarewicz, and S. Balabanov Aurora kinase inhibitor PHA-739358 suppresses growth of hepatocellular carcinoma in vitro and in a xenograft mouse model Neoplasia 11 2009 934 944
28. H. Yang, L. He, P. Kruk, S.V. Nicosia, and J.Q. Cheng Aurora-A induces cell survival and chemoresistance by activation of Akt through a p53-dependent manner in ovarian cancer cells Int J Cancer 119 2006 2304 2312 (Pubitemid 44546949)
29. P. Workman Drugging the cancer kinome: progress and challenges in developing personalized molecular cancer therapeutics Cold Spring Harb Symp Quant Biol 70 2005 499 515 (Pubitemid 44124907)
30. M.A. Lampson, K. Renduchitala, A. Khodjakov, and T.M. Kapoor Correcting improper chromosome-spindle attachments during cell division Nat Cell Biol 6 2004 232 237 (Pubitemid 38344361)
31. M. Lampson, K. Renduchitala, A. Khodjakov, and T. Kapoor Correcting improper chromosome-spindle attachments during cell division Nat Cell Biol 6 2004 232 237 (Pubitemid 38344361)
32. P.J. Collins, L.K. Hennessy, C.S. Leibelt, R.K. Roby, D.J. Reeder, and P.A. Foxall Developmental validation of a single-tube amplification of the 13 CODIS STR loci, D2S1338, D19S433, and amelogenin: the AmpFlSTR Identifiler PCR Amplification Kit J Forensic Sci 49 2004 1265 1277 (Pubitemid 39453184)
33. R.E. Tiedemann, Y.X. Zhu, J. Schmidt, H. Yin, C.-X. Shi, and Q. Que Kinome-wide RNAi studies in human multiple myeloma identify vulnerable kinase targets, including a lymphoid-restricted kinase, GRK6 Blood 115 2010 1594 1604
34. E.A. Harrington, D. Bebbington, J. Moore, R.K. Rasmussen, A.O. Ajose-Adeogun, and T. Nakayama VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo Nat Med 10 2004 262 267 (Pubitemid 38667616)
35. R.D. Carvajal, A. Tse, and G.K. Schwartz Aurora kinases: new targets for cancer therapy Clin Cancer Res 12 2006 6869 6875 (Pubitemid 44974478)
36. S.L. Warner, S. Bashyam, H. Vankayalapati, D.J. Bearss, H. Han, and D. Mahadevan Identification of a lead small-molecule inhibitor of the Aurora kinases using a structure-assisted, fragment-based approach Mol Cancer Ther 5 2006 1764 1773 (Pubitemid 44323244)
37. M. Ebert, M. Yokoyama, H. Friess, M.S. Kobrin, M.W. Buchler, and M. Korc Induction of platelet-derived growth factor A and B chains and over-expression of their receptors in human pancreatic cancer Int J Cancer 62 1995 529 535
38. R.F. Hwang, K. Yokoi, C.D. Bucana, R. Tsan, J.J. Killion, and D.B. Evans Inhibition of platelet-derived growth factor receptor phosphorylation by STI571 (Gleevec) reduces growth and metastasis of human pancreatic carcinoma in an orthotopic nude mouse model Clin Cancer Res 9 2003 6534 6544 (Pubitemid 38031842)
39. C.H. Baker, J.G. Trevino, J.M. Summy, F. Zhang, A. Caron, and M. Nesbit Inhibition of PDGFR phosphorylation and Src and Akt activity by GN963 leads to therapy of human pancreatic cancer growing orthotopically in nude mice Int J Oncol 29 2006 125 138
40. W.R. Greco, G. Bravo, and J.C. Parsons The search for synergy: a critical review from a response surface perspective Pharmacol Rev 47 1995 331 385
41. M.R. Green, J.E. Woolery, and D. Mahadevan Update on Aurora kinase targeted therapeutics in oncology Expert Opin Drug Discov 6 2011 291 307
42. Cheung CH, Coumar MS, Chang JY, Hsieh HP. Aurora kinase inhibitor patents and agents in clinical testing: an update (2009-10). This article is an update to aurora kinase inhibitors review, which appeared in: Expert Opin Ther Patents 2009;19:1-36 and Expert Opin Investig Drugs 2009;18:1-20, Expert Opin Ther Patents 21;857-84; 2011.
43. N. Keen, and S. Taylor Aurora-kinase inhibitors as anticancer agents Nat Rev Cancer 4 2004 927 936 (Pubitemid 39626216)
44. D.S. Boss, J.H. Beijnen, and J.H. Schellens Clinical experience with aurora kinase inhibitors: a review Oncologist 14 2009 780 793
45. S.R. Bartz, Z. Zhang, J. Burchard, M. Imakura, M. Martin, and A. Palmieri Small interfering RNA screens reveal enhanced cisplatin cytotoxicity in tumor cells having both BRCA network and TP53 disruptions Mol Cell Biol 26 2006 9377 9386 (Pubitemid 44904431)
46. D.O. Azorsa, I.M. Gonzales, G.D. Basu, A. Choudhary, S. Arora, and K.M. Bisanz Synthetic lethal RNAi screening identifies sensitizing targets for gemcitabine therapy in pancreatic cancer J Transl Med 7 2009 43
47. C.H. Diep, R.M. Munoz, A. Choudhary, D.D. Von Hoff, and H. Han Synergistic effect between erlotinib and MEK inhibitors in KRAS wild-type human pancreatic cancer cells Clin Cancer Res 17 2011 2744 2756
48. S. Ramaswamy Rational design of cancer-drug combinations N Engl J Med 357 2007 299 300 (Pubitemid 47080397)
49. A.W. Whitehurst, B.O. Bodemann, J. Cardenas, D. Ferguson, L. Girard, and M. Peyton Synthetic lethal screen identification of chemosensitizer loci in cancer cells Nature 446 2007 815 819 (Pubitemid 46582032)
50. V. Giroux, J. Iovanna, and J.C. Dagorn Probing the human kinome for kinases involved in pancreatic cancer cell survival and gemcitabine resistance FASEB J 20 2006 1982 1991 (Pubitemid 44953898)
51. D.G. Hayward, and A.M. Fry Nek2 kinase in chromosome instability and cancer Cancer Lett 237 2006 155 166 (Pubitemid 43777084)
52. H. Katayama, H. Zhou, Q. Li, M. Tatsuka, and S. Sen Interaction and feedback regulation between STK15/BTAK/Aurora-A kinase and protein phosphatase 1 through mitotic cell division cycle J Biol Chem 276 2001 46219 46224
53. P. Meraldi, and E.A. Nigg Centrosome cohesion is regulated by a balance of kinase and phosphatase activities J Cell Sci 114 2001 3749 3757 (Pubitemid 33041056)
54. H.J. Nam, S. Chae, S.H. Jang, H. Cho, and J.H. Lee The PI3K-Akt mediates oncogenic Met-induced centrosome amplification and chromosome instability Carcinogenesis 31 2010 1531 1540
55. K. Kiehne, K.H. Herzig, and U.R. Folsch c-met expression in pancreatic cancer and effects of hepatocyte growth factor on pancreatic cancer cell growth Pancreas 15 1997 35 40 (Pubitemid 27527357)
56. M. Ebert, M. Yokoyama, H. Friess, M.W. Buchler, and M. Korc Coexpression of the c-met proto-oncogene and hepatocyte growth factor in human pancreatic cancer Cancer Res 54 1994 5775 5778 (Pubitemid 24375202)
57. J. Kleeff, H. Maruyama, T. Ishiwata, H. Sawhney, H. Friess, and M.W. Buchler Bone morphogenetic protein 2 exerts diverse effects on cell growth in vitro and is expressed in human pancreatic cancer in vivo Gastroenterology 116 1999 1202 1216 (Pubitemid 29203031)
58. D.H. Vlecken, and C.P. Bagowski LIMK1 and LIMK2 are important for metastatic behavior and tumor cell-induced angiogenesis of pancreatic cancer cells Zebrafish 6 2009 433 439
59. S. Chen, T. Auletta, O. Dovirak, C. Hutter, K. Kuntz, and S. El-ftesi Copy number alterations in pancreatic cancer identify recurrent PAK4 amplification Cancer Biol Ther 7 2008 1793 1802
60. A.C. Kimmelman, A.F. Hezel, A.J. Aguirre, H. Zheng, J.H. Paik, and H. Ying Genomic alterations link Rho family of GTPases to the highly invasive phenotype of pancreas cancer Proc Natl Acad Sci USA 105 2008 19372 19377
61. M.D. Abramoff, P.J. Magalhaes, and S.J. Ram Image processing with ImageJ Biophotonics Int 11 2004 36 42